Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service EP ablation cases in Vermont: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (230 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 4 | 111 | 13% |
| 2020 | 4 | 132 | 16% |
| 2021 | 5 | 188 | 22% |
| 2022 | 6 | 173 | 30% |
| 2023 | 5 | 200 | 33% |
| 2024 | 6 | 187 | 35% |
| 2025 from claims | – | 294 238–345 | 34% |
| 2026 forecast | – | 390 306–490 | 14% |
| 2027 forecast | – | 441 327–583 | 10% |
| 2028 forecast | – | 497 352–687 | 7% |
| 2029 forecast | – | 561 381–804 | 4% |
| 2030 forecast | – | 631 414–937 | 1% |
AF, SVT, and VT catheter ablation. Professional codes (what the surgeon bills): CPT 93656, 93653, 93654; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Vermont; 4 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 138 | 7,854+9.3%/yr | +9.3%/yr | 3.6 | 0% | 15,300 in 2030+12%/yr |
| Pennsylvania | 131 | 5,803+11%/yr | +11%/yr | 3.5 | 0% | 11,400 in 2030+12%/yr |
| Massachusetts | 73 | 4,222+12%/yr | +12%/yr | 4.0 | 0% | 9,560 in 2030+15%/yr |
| New Jersey | 61 | 3,055+5.7%/yr | +5.7%/yr | 2.5 | 0% | 5,460 in 2030+10%/yr |
| Connecticut | 25 | 921+6%/yr | +6%/yr | 2.3 | 0% | 1,750 in 2030+11%/yr |
| New Hampshire | 11 | 595+16%/yr | +16%/yr | 2.3 | 0% | 1,590 in 2030+18%/yr |
| Maine | 10 | 404+10%/yr | +10%/yr | 2.1 | 0% | 870 in 2030+14%/yr |
| Rhode Island | 8 | 382+4.9%/yr | +4.9%/yr | 3.4 | 0% | 920 in 2030+16%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 10 | 413+2.4%/yr | +2.4%/yr | 3.70.8× | 0% | 710 in 2030+9.3%/yr |
| LAA occlusion & loop recorders | 3 | 103−6.7%/yr | −6.7%/yr | 0.80.3× | 0% | 200 in 2030+12%/yr |
EP ablation in every state, and its device makers · Every procedure market in Vermont · Every state · Compare with New York
Johnson & Johnson MedTech leads with 99% of company spending on these surgeons in 2025, +55 pts on 2024.
In 2025, 2 companies reported engagement with Vermont’s surgeons worth $7,439 in consulting, speaking, meals and travel tied to these products, about $1,240 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 102 clearances and approvals in the category, 5 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.